Presenting signs and clinical outcome in dogs with metaphyseal osteopathy: 39 cases (2009–2018)

• Published in: Journal of small animal practice 2023-01, Vol.64 (1), p.35-42
• Main Authors: Robertson, A. L., Black, V. L., Villedieu, E., Clarke, K. E., Faux, I., Major, A., Adamantos, S.
• Format: Article
• Language: English
• Subjects: Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Bone diseases; Clinical outcomes; Clinical significance; Diagnosis; Dog Diseases - diagnostic imaging; Dog Diseases - drug therapy; Dogs; Female; Fever; Medical records; Nonsteroidal anti-inflammatory drugs; Original; Osteopathic medicine; Pain perception; Prednisolone; Prednisolone - therapeutic use; Radiography; Retrospective Studies; Vaccination
• ISSN: 0022-4510; 1748-5827
• DOI: 10.1111/jsap.13554

Objective To describe the presenting signs, concurrent conditions, treatment and outcome of dogs with metaphyseal osteopathy. Materials and Methods Multi‐centre retrospective review of medical records from January 2009 to September 2018 at four referral centres to identify dogs with a radiographic diagnosis of metaphyseal osteopathy. Results Thirty‐nine dogs were identified. The median age at onset was 14 weeks old (range, 8 to 32 weeks old). There was a higher proportion of male dogs (29 of 39 male entire, nine of 39 female entire, one of 39 female neutered and no male neutered dogs). Where information was available, median time from the most recent vaccination was 20 days (range, 2 to 144 days). The most commonly recorded clinical signs were pyrexia (34 of 39), lethargy (32 of 39), pain (30 of 39), and being non‐ambulatory (17 of 39). Thirty‐five dogs required hospitalisation for analgesia and supportive care, 19 of 39 were discharged on prednisolone (median dose 2.0 mg/kg/day; range, 0.9 to 2.6 mg/kg/day), 18 of 39 were discharged on non‐steroidal anti‐inflammatories, two of 39 did not receive NSAIDs or prednisolone at any time point. The median duration of hospitalisation for those admitted was 5 days (range, 1 to 21 days). Where follow‐up was available, relapse occurred in eight of 25 cases before reaching skeletal maturity. At the time of metaphyseal osteopathy diagnosis, five of 39 cases had concurrent conditions. Where follow‐up was available, four of 25 developed future immune‐mediated conditions. Clinical Significance Metaphyseal osteopathy should be considered in non‐ambulatory painful young dogs. Some dogs developed future immune‐mediated conditions, which may support the hypothesis that metaphyseal osteopathy is an autoinflammatory bone disorder. Further studies with a larger cohort are required to determine the clinical significance of this.